Drug news
NICE endorses Victrelis (Merck Inc.)for Hepatitis C genotype 1 infection
In its final draft guidance, NICE recommends Victrelis (boceprevir) from Merck Inc., in combination with Roche�s Pegasus (peginterferon alfa) and Copegus (ribavirin) injections,as an option for the treatment of genotype 1 Chronic Hepatitis C in adults with compensated liver disease.A final endorsement is expected next month. Hepatitis C has a poor diagnosis and low treatment compliance rate, with a high annual incidence of new infection.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins